Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal

Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal

Saved in:

Bibliographic Details
Main Authors:	F. H. van Bruggen, H. J. Luijendijk
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	type 2 MI PCSK 9 inhibitors GLP 1 analog SLGT inhibitors efficacy outcomes safety outcomes
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2025.1564432/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Indirect comparison of the efficacy and safety of alirocumab and evolocumab on major cardiovascular events: a systematic review and network meta-analysis
by: Leyu Xu, et al.
Published: (2025-06-01)

Effectiveness of inclisiran lipid-lowering therapy in patients with atherosclerotic cardiovascular disease in Moscow healthcare
by: A. I. Sapina, et al.
Published: (2024-06-01)

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
by: Maram H. Abduljabbar
Published: (2024-11-01)

PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
by: Simon Rauterberg, et al.
Published: (2025-01-01)

PCSK9 inhibitors – new era of dyslipidemia treatment - effectiveness in reducing low-density lipoprotein (LDL-C) and cardiovascular risk
by: Radosław Szydłowski, et al.
Published: (2024-12-01)

Observational study of inclisiran effectiveness in Moscow healthcare
by: A. I. Sapina, et al.
Published: (2023-12-01)

PCSK9 in T-cell function and the immune response
by: Yuying Wang, et al.
Published: (2024-12-01)

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to tackle central nervous system diseases: role as a promising approach
by: Xiaoxiao Zheng, et al.
Published: (2025-07-01)

Inhibitors in the Management of Patients with Atherosclerotic Cardiovascular Diseases: Guidelines and Reimbursement Issues
by: M. V. Zhuravleva, et al.
Published: (2020-09-01)

Efficacy and safety of different proprotein convertase subtilisin/kexin type 9 inhibitors in the general population and solid organ transplant recipients: a network meta-analysis
by: Bohan Luo, et al.
Published: (2025-08-01)

Atherosclerosis and inflammation – the path from pathogenesis to treatment: review of the current state of the issue (part 2)
by: A. A. Avagimyan, et al.
Published: (2025-07-01)

Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023-03-01)

Prospects of Using PCSK9 Inhibitors for Acute Coronary Syndrome
by: A. M. Namitokov, et al.
Published: (2024-04-01)

Cardiovascular risk management beyond statins: review of new therapies available in Italy
by: Maurizio Capuozzo, et al.
Published: (2025-07-01)

Modulation of atherogenesis biomarkers by PCSK9 inhibitors in Lp(a)-stimulated human coronary artery endothelial cells
by: Rahayu Zulkapli, et al.
Published: (2025-07-01)

Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties: a randomized controlled trial
by: Andreja Rehberger Likozar, et al.
Published: (2025-02-01)

Mechanisms of action and therapeutic potential of PCSK9-regulating drugs
by: Chenrui Qi, et al.
Published: (2025-12-01)

PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders
by: O. L. Barbarash, et al.
Published: (2020-09-01)

HIGH INTENSITY HYPOLIPIDEMIC THERAPY AND DECREASED LEVEL OF LOW DENSITY LIPOPROTEIDES CHOLESTEROL: IS THE APPROACH JUSTIFIED? POINT OF VIEW
by: M. G. Bubnova
Published: (2018-07-01)

PCSK9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome
by: Wang Liang, et al.
Published: (2025-01-01)

Lower body mass index is associated with the achievement of target LDL in patients using PCSK9 inhibitors in Taiwan
by: Kuan-Chieh Tu, et al.
Published: (2025-03-01)

A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-07-01)

Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-08-01)

Lipid-lowering treatment in the improvement of outcomes in patients with atherosclerotic cardiovascular disease and diabetes mellitus: the role of PCSK9 inhibitors
by: G. R. Galstyan, et al.
Published: (2018-12-01)

PCSK9 is upregulated and correlated with more severe disease condition but fails to predict treatment outcomes in psoriasis patients
by: Xuwen Yin, et al.
Published: (2025-12-01)

Expanding therapeutic horizons: glucagon-like peptide-1 receptor agonists and sodium glucose transporter-2 inhibitors in poly cystic ovarian syndrome: a comprehensive review including systematic review and network meta-analysis of randomized clinical trials
by: Kannan Sridharan, et al.
Published: (2025-05-01)

Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis
by: Shengxuan Zhang, et al.
Published: (2024-11-01)

Application of a PCSK9 inhibitor in the treatment of lipid disorders – a comprehensive literature
by: Piotr Rzyczniok, et al.
Published: (2025-05-01)

Intensification of lipid-lowering therapy in very high-risk patients: potential of combination with PCSK9 inhibitors
by: D. Yu. Sedykh, et al.
Published: (2022-07-01)

Design of the “EAST” strategy in patients with symptomatic intracranial atherosclerotic stenosis
by: Jiaqi Dai, et al.
Published: (2025-05-01)

Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis
by: Yuhua Jiang, et al.
Published: (2025-02-01)

Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
by: Stefan D. Anker
Published: (2019-12-01)

Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease
by: A. E. Nikitin, et al.
Published: (2020-03-01)

Evaluation of Intensive Statins and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Intracranial Artery Plaque Stability: A Prospective Single‐Arm Study
by: Weiqi Zeng, et al.
Published: (2025-01-01)

Evolocumab Added to Statin Is Associated With Intracranial Atherosclerotic Plaque Regression Compared With Statin Alone
by: Xinzhi Hu, et al.
Published: (2025-08-01)

PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
by: A. V. Blokhina, et al.
Published: (2022-01-01)

Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of coronary heart disease: a study protocol for a randomized controlled trial in Dalian, China
by: Xing Gong, et al.
Published: (2025-01-01)

PCSK9 Inhibitors: The Evolving Future
by: Bijay Mukesh Jeswani, et al.
Published: (2024-11-01)

Gain of function variants in PCSK9 gene in high risk patients after myocardial infarction with increased lipoprotein (a) values and treated with statins
by: Sabina Ugovšek, et al.
Published: (2025-07-01)

Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
by: A. Yu. Filatova, et al.
Published: (2019-06-01)